Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REIMAGINE 5 (vs tirzepatide 5 mg)

REIMAGINE 5 (vs tirzepatide 5 mg)

CagriSema · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
t2d
Official title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2024-11 → 2026-06
Participants
1023
Duration
60 weeks
Registry
NCT06534411

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 1.0/1.0 mg vs tirzepatide 5 mg (active)t2d60—−12.4 %—−1.7——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (2)
  • CagriSema 1.0/1.0 mg · weight_eff · company announcement
    CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss
  • CagriSema 1.0/1.0 mg · hba1c · company announcement
    1.71% (CagriSema) vs. 1.67% (tirzepatide) – non-inferior

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REIMAGINE 5 (vs tirzepatide 5 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.